Valaciclovir 복용 후 중추신경계 부작용을 보였던 복막투석 환자 1예
A Case of Neurotoxicity Induced by Valaciclovir in a Continuous Ambulatory Peritoneal Dialysis Patient
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Valaciclovir is metabolized to acyclovir after ingestion and thereafter exerts its antiviral activity. Because of its superior pharmacokinetic profile, it has quickly replaced acyclovir in the treatment of herpesvirus infection. Neurotoxicity caused by valaciclovir has been reported, however, among patients with pre-existing impaired renal function. This paper reports a case of neurotoxicity of valaciclovir in a patient with end-stage renal disease who was undergoing continuous ambulatory peritoneal dialysis (CAPD). A 67-year-old female on CAPD took 500 mg of valaciclovir twice for herpes zoster. After she took her second dose orally, she developed confusion and disorientation, along with involuntary movements. Her mental confusion progressed to a coma. Discontinuation of valaciclovir showed no rapid improvement. There- fore, hemodialysis was started. After two sessions of hemodialysis, the patient became alert; and after four sessions of hemodialysis, her neurological abnormalities were completely reversed. In conclusion, valaciclovir can induce life-threatening neurotoxicity, especially in CAPD patients, even with appropriate dose reduction, which can be effectively managed by hemodialysis.
Abstract
Valaciclovir is metabolized to acyclovir after ingestion and thereafter exerts its antiviral activity. Because of its superior pharmacokinetic profile, it has quickly replaced acyclovir in the treatment of herpesvirus infection. Neurotoxicity caused by valaciclovir has been reported, however, among patients with pre-existing impaired renal function. This paper reports a case of neurotoxicity of valaciclovir in a patient with end-stage renal disease who was undergoing continuous ambulatory peritoneal dialysis (CAPD). A 67-year-old female on CAPD took 500 mg of valaciclovir twice for herpes zoster. After she took her second dose orally, she developed confusion and disorientation, along with involuntary movements. Her mental confusion progressed to a coma. Discontinuation of valaciclovir showed no rapid improvement. There- fore, hemodialysis was started. After two sessions of hemodialysis, the patient became alert; and after four sessions of hemodialysis, her neurological abnormalities were completely reversed. In conclusion, valaciclovir can induce life-threatening neurotoxicity, especially in CAPD patients, even with appropriate dose reduction, which can be effectively managed by hemodialysis.
참고문헌 (11)
- Soul-Lawton J, "Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans", Antimicrob Agents Chemother, 39, pp.2759~2764 (1995)
- Mac Dougall C, "Pharmacokinetics of valaciclovir", J Antimicrob Chemother, 53, pp.899~901 (2004)
- Haefeli WE, "Acyclovirinduced neurotoxicity: concentration-side effect relationship in acyclovir overdose", Am J Med, 94, pp.212~215 (1993)
- Laskin OL, "Effect of renal failure on the pharmacokinetics of acyclovir", Am J Med, 73, pp.197~201 (1982)
- Stathoulopoulou F, "Evaluation of valaciclovir dosage reduction in continuous ambulatory peritoneal dialysis patients", Nephron, 91, pp.164~166 (2002)
- Izzedine H, "Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study", Am J Nephrol, 21, pp.162~164 (2001)
- Helldén A, "High serum concentrations of the acyclovir main metabolite 9-carboxymethoxymethylguanine in renal failure patients with acyclovir-related neuropsychiatric side effects: an observational study", Nephrol Dial Transplant, 18, pp.1135~1141 (2003)
- Sigaloff KC, "Herpes zoster-associated encephalitis in a patient undergoing CAPD: case report and literature review", Perit Dial Int, 27, pp.391~394 (2007)
- Steiner I, "The neurotropic herpes viruses: herpes simplex and varicella-zoster", Lancet Neurol, 6, pp.1015~1028 (2007)
- Asahi T, "Valacyclovir neurotoxicity: clinical experience and review of the literature", Eur J Neurol, 16, pp.457~460 (2009)